{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:33:45Z","timestamp":1791614025584,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T00:00:00Z","timestamp":1156464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    To better understand the spectrum of adult acute myeloid leukaemia (AML) associated with core binding factor (CBF) translocations, 370 patients with newly diagnosed CBF\u2010associated AML were analysed. Patients\u2019 age ranged from 16\u201383\u2003years (median 39\u2003years) with a slight male predominance (55%); 53% had inv(16); 47% had t(8;21). Patients with t(8;21) tended to be younger (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b7056), have lower peripheral blood white cell counts (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030\u00b70001) and were more likely to have additional cytogenetic abnormalities (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030\u00b70001). Loss of sex chromosome, del(9q) and complex abnormalities were more common among patients with t(8;21), while +22 and +21 were more common with inv(16). Overall, 87% [95% confidence interval (CI) 83\u201390%] of patients achieved complete response (CR) with no difference between t(8;21) and inv(16); however, the CR rate was lower in older patients due to increased resistant disease and early deaths. Ten\u2010year overall survival (OS) was 44% (95% CI 39\u201350%) and, in multivariate analysis, was shorter with increasing age (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030\u00b70001), increased peripheral blast percentage (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b70006), in patients with complex cytogenetic abnormalities in addition to the CBF translocation (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b7021), and in patients with t(8;21) (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030\u00b7025). OS was superior in patients who received regimens with high\u2010dose cytarabine, a combination of fludarabine and intermediate\u2010dose cytarabine, or haematopoietic cell transplantation.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2141.2006.06276.x","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T06:55:22Z","timestamp":1156488922000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":229,"title":["The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations"],"prefix":"10.1111","volume":"135","author":[{"given":"Frederick R.","family":"Appelbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn L.","family":"Slovak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Gundacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon W.","family":"Dewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry R.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu H.","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0354"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3767"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0772"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.012"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3640"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04362.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.314"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392301"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190412331283288"},{"key":"e_1_2_6_12_1","first-page":"323a","article-title":"A phase II trial of subcutaneous recombinant human interleukin 11 (rhIL\u201011) with subcutaneous recombinant human granulocyte\u2010macrophage colony stimulating factor (rhGM\u2010CSF) in patients with acute myeloid leukemia (AML) receiving high\u2010dose cytarabine during induction: ECOG 3997","volume":"96","author":"Cripe L.D.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3527"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(02)00018-7"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3575"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.10.3607"},{"key":"e_1_2_6_17_1","first-page":"2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"92","author":"Grimwade D.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204593"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3212"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8351518"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.15.610"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3517"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05445.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009054882"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.457.bloodjournal862457"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1686"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.012"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1466"},{"key":"e_1_2_6_29_1","first-page":"1288","article-title":"Fifty\u2010one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor","volume":"10","author":"Schoch C.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_30_1","first-page":"1082","article-title":"The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups","volume":"89","author":"Schoch C.","year":"2004","journal-title":"Hematologica"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4075"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc840"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2006.06276.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2006.06276.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T10:55:15Z","timestamp":1695898515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2006.06276.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,18]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1111\/j.1365-2141.2006.06276.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06276.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,18]]},"assertion":[{"value":"2006-09-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}